ServiceNow Stock Outlook Remains Promising
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5h ago
0mins
Source: Yahoo Finance
- Price Target Revision: Truist lowered ServiceNow's price target from $240 to $175 while maintaining a Buy rating, indicating that despite market concerns over terminal value, short-term fundamentals remain solid, reflecting a focus on AI narratives.
- AI Competitiveness Enhancement: Jim Cramer highlighted ServiceNow's increasing competitiveness in the AI space, especially as vendors with seat-based models underperform, suggesting a strategic shift towards AI applications to enhance market positioning.
- Growth Potential: Goldman Sachs added ServiceNow to its US Conviction List, maintaining a Buy rating with a $216 price target, anticipating the company to achieve 20% organic growth annually through 2029, showcasing robust expansion opportunities in new domains.
- Intelligent Platform Advantage: ServiceNow's Now Platform offers comprehensive workflow automation solutions embedded with AI and machine learning, aimed at boosting productivity and maximizing business outcomes, further solidifying its market leadership in digital transformation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFC
Wall Street analysts forecast TFC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TFC is 54.38 USD with a low forecast of 47.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
8 Buy
5 Hold
1 Sell
Moderate Buy
Current: 55.140
Low
47.00
Averages
54.38
High
63.00
Current: 55.140
Low
47.00
Averages
54.38
High
63.00
About TFC
Truist Financial Corporation is a financial services company. As a commercial bank, it offers a range of products and services through its wholesale and consumer businesses, including consumer and small business banking, commercial banking, corporate and investment banking, wealth management, payments, and specialized lending businesses. Its segments include Consumer and Small Business Banking (CSBB) and Wholesale Banking (WB). CSBB segment serves retail, premier, and small business clients, providing transaction, money market, savings, time deposits and payment services, credit cards, loans, and mortgages through digital banking, a network of community banking branches, ATMs, virtual service centers, and other channels. WB segment provides a comprehensive set of products, solutions, and advisory services to commercial, corporate, institutional and wealth clients. It also invests in certain affordable housing, new market tax credit, and renewable energy tax credit investments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMD Stock Rating Updates and Future Outlook
- Rating Adjustments: UBS lowered AMD's price target from $330 to $310 while maintaining a Buy rating, highlighting AMD's outperformance against peers like Broadcom and Nvidia in 2023, indicating strong market competitiveness.
- Earnings Outlook: Despite a $1 billion cut in the gaming business, analysts believe AMD's CPU and GPU fundamentals remain strong, with projections of over $11 EPS by 2027 and more than $15 by 2028, showcasing long-term growth potential.
- Truist Rating Upgrade: Truist raised AMD's price target from $277 to $283, keeping a Buy rating and recommending investors buy on weakness, emphasizing the strength of the company's long-term growth narrative.
- Market Positioning: As a global semiconductor company focused on high-performance computing and graphics technologies, AMD's innovations drive the future of data centers, embedded systems, gaming, and PC markets, although some AI stocks may offer greater upside potential.
See More
ServiceNow Stock Outlook Remains Promising
- Price Target Revision: Truist lowered ServiceNow's price target from $240 to $175 while maintaining a Buy rating, indicating that despite market concerns over terminal value, short-term fundamentals remain solid, reflecting a focus on AI narratives.
- AI Competitiveness Enhancement: Jim Cramer highlighted ServiceNow's increasing competitiveness in the AI space, especially as vendors with seat-based models underperform, suggesting a strategic shift towards AI applications to enhance market positioning.
- Growth Potential: Goldman Sachs added ServiceNow to its US Conviction List, maintaining a Buy rating with a $216 price target, anticipating the company to achieve 20% organic growth annually through 2029, showcasing robust expansion opportunities in new domains.
- Intelligent Platform Advantage: ServiceNow's Now Platform offers comprehensive workflow automation solutions embedded with AI and machine learning, aimed at boosting productivity and maximizing business outcomes, further solidifying its market leadership in digital transformation.
See More
Gilead Sciences Rated as One of the Most Profitable NASDAQ Stocks
- Price Target Increase: Truist Securities raised its price target for Gilead Sciences from $140 to $145 while maintaining a Buy rating, indicating strong confidence in the company's future performance ahead of its upcoming Q4 earnings report.
- Drug Expectations Adjustment: Truist noted in its research report that it revised estimates for YEZTUGO, a drug aimed at reducing HIV-1 risk, highlighting the growing recognition of Gilead's efforts in this area, which could drive future sales growth.
- Citi's Target Price Boost: On the same day, Citigroup raised its price target for Gilead Sciences from $140 to $156, keeping a Buy rating, reflecting an optimistic outlook for the biopharmaceutical sector, especially with reduced policy risks.
- Promising Market Outlook: Gilead Sciences focuses on developing medicines for life-threatening diseases such as HIV, viral hepatitis, and cancer, and while analysts suggest certain AI stocks may offer greater upside, Gilead's solid performance continues to attract investor interest.
See More
Tesla's Stock Fluctuations and Strategic Adjustments
- Stock Performance: Tesla (TSLA) shares have risen 6.4% over the past year but are down 1.7% year-to-date, indicating cautious investor sentiment regarding its future performance, which could impact confidence.
- Price Target Adjustment: Truist has slightly lowered Tesla's price target from $439 to $438 while maintaining a Hold rating, reflecting analysts' conservative outlook on its short-term growth potential.
- Strategic Shift: Tesla is discontinuing the production of its Model S and X vehicles and integrating AI-related targets into its 2026 plans, indicating a significant shift in business strategy that may affect future product lines and profitability.
- Market Confidence: CNBC host Jim Cramer remains bullish on Tesla, asserting it is more of a technology company than an automaker, a perspective that may attract more investor interest in its technological innovation potential.
See More
Booz Allen Hamilton Faces Setback After Tax Data Leak
- Stock Volatility: Booz Allen Hamilton Holding Corporation (NYSE:BAH) has seen its shares decline by 31% over the past year, although they have risen by 4% year-to-date, indicating market concerns about its future performance and volatility.
- Contract Termination Impact: The Treasury Department terminated contracts with Booz Allen due to a tax data leak, resulting in an estimated annual revenue loss of approximately $4.8 million, which, while a small fraction of its $11.41 billion annual revenue, still negatively impacts the company's reputation.
- Analyst Rating Changes: Truist reiterated a Hold rating for Booz Allen with a price target of $98, while DA Davidson raised its target from $73 to $81, reflecting differing views among analysts regarding the company's future profitability.
- Future Earnings Expectations: DA Davidson increased Booz Allen's earnings estimates for 2026 and 2027 to $6.10 and $6.75, respectively, demonstrating confidence in the company's long-term growth potential despite facing short-term challenges.
See More
Truist Raises Flywire Price Target Amid Optimism
- Analyst Price Target Increase: Truist analyst Matthew Coad raised Flywire's price target from $16 to $17 with a Buy rating, reflecting confidence in the company's future performance despite facing challenging year-over-year comparisons.
- Cautious 2026 Outlook: Analysts noted that while solid quarterly results are anticipated, management might issue conservative 2026 guidance to reset market expectations, which could impact short-term stock performance.
- Improving Education Environment: Stephens analyst Charles Nabhan upgraded Flywire from Equal Weight to Overweight and raised the price target from $17 to $19, driven by an improving higher education environment, indicating the company's potential to outperform expectations in the future.
- Growth Levers and Valuation: Analysts highlighted Flywire's various growth levers, deeply discounted valuation, and a strong track record of beat-and-raise earnings quarters as primary reasons for the upgrade, suggesting robust growth momentum in the competitive FinTech sector.
See More
AMD Stock Rating Updates and Future Outlook
- Rating Adjustments: UBS lowered AMD's price target from $330 to $310 while maintaining a Buy rating, highlighting AMD's outperformance against peers like Broadcom and Nvidia in 2023, indicating strong market competitiveness.
- Earnings Outlook: Despite a $1 billion cut in the gaming business, analysts believe AMD's CPU and GPU fundamentals remain strong, with projections of over $11 EPS by 2027 and more than $15 by 2028, showcasing long-term growth potential.
- Truist Rating Upgrade: Truist raised AMD's price target from $277 to $283, keeping a Buy rating and recommending investors buy on weakness, emphasizing the strength of the company's long-term growth narrative.
- Market Positioning: As a global semiconductor company focused on high-performance computing and graphics technologies, AMD's innovations drive the future of data centers, embedded systems, gaming, and PC markets, although some AI stocks may offer greater upside potential.
See More
ServiceNow Stock Outlook Remains Promising
- Price Target Revision: Truist lowered ServiceNow's price target from $240 to $175 while maintaining a Buy rating, indicating that despite market concerns over terminal value, short-term fundamentals remain solid, reflecting a focus on AI narratives.
- AI Competitiveness Enhancement: Jim Cramer highlighted ServiceNow's increasing competitiveness in the AI space, especially as vendors with seat-based models underperform, suggesting a strategic shift towards AI applications to enhance market positioning.
- Growth Potential: Goldman Sachs added ServiceNow to its US Conviction List, maintaining a Buy rating with a $216 price target, anticipating the company to achieve 20% organic growth annually through 2029, showcasing robust expansion opportunities in new domains.
- Intelligent Platform Advantage: ServiceNow's Now Platform offers comprehensive workflow automation solutions embedded with AI and machine learning, aimed at boosting productivity and maximizing business outcomes, further solidifying its market leadership in digital transformation.
See More
Gilead Sciences Rated as One of the Most Profitable NASDAQ Stocks
- Price Target Increase: Truist Securities raised its price target for Gilead Sciences from $140 to $145 while maintaining a Buy rating, indicating strong confidence in the company's future performance ahead of its upcoming Q4 earnings report.
- Drug Expectations Adjustment: Truist noted in its research report that it revised estimates for YEZTUGO, a drug aimed at reducing HIV-1 risk, highlighting the growing recognition of Gilead's efforts in this area, which could drive future sales growth.
- Citi's Target Price Boost: On the same day, Citigroup raised its price target for Gilead Sciences from $140 to $156, keeping a Buy rating, reflecting an optimistic outlook for the biopharmaceutical sector, especially with reduced policy risks.
- Promising Market Outlook: Gilead Sciences focuses on developing medicines for life-threatening diseases such as HIV, viral hepatitis, and cancer, and while analysts suggest certain AI stocks may offer greater upside, Gilead's solid performance continues to attract investor interest.
See More
Tesla's Stock Fluctuations and Strategic Adjustments
- Stock Performance: Tesla (TSLA) shares have risen 6.4% over the past year but are down 1.7% year-to-date, indicating cautious investor sentiment regarding its future performance, which could impact confidence.
- Price Target Adjustment: Truist has slightly lowered Tesla's price target from $439 to $438 while maintaining a Hold rating, reflecting analysts' conservative outlook on its short-term growth potential.
- Strategic Shift: Tesla is discontinuing the production of its Model S and X vehicles and integrating AI-related targets into its 2026 plans, indicating a significant shift in business strategy that may affect future product lines and profitability.
- Market Confidence: CNBC host Jim Cramer remains bullish on Tesla, asserting it is more of a technology company than an automaker, a perspective that may attract more investor interest in its technological innovation potential.
See More
Booz Allen Hamilton Faces Setback After Tax Data Leak
- Stock Volatility: Booz Allen Hamilton Holding Corporation (NYSE:BAH) has seen its shares decline by 31% over the past year, although they have risen by 4% year-to-date, indicating market concerns about its future performance and volatility.
- Contract Termination Impact: The Treasury Department terminated contracts with Booz Allen due to a tax data leak, resulting in an estimated annual revenue loss of approximately $4.8 million, which, while a small fraction of its $11.41 billion annual revenue, still negatively impacts the company's reputation.
- Analyst Rating Changes: Truist reiterated a Hold rating for Booz Allen with a price target of $98, while DA Davidson raised its target from $73 to $81, reflecting differing views among analysts regarding the company's future profitability.
- Future Earnings Expectations: DA Davidson increased Booz Allen's earnings estimates for 2026 and 2027 to $6.10 and $6.75, respectively, demonstrating confidence in the company's long-term growth potential despite facing short-term challenges.
See More
Truist Raises Flywire Price Target Amid Optimism
- Analyst Price Target Increase: Truist analyst Matthew Coad raised Flywire's price target from $16 to $17 with a Buy rating, reflecting confidence in the company's future performance despite facing challenging year-over-year comparisons.
- Cautious 2026 Outlook: Analysts noted that while solid quarterly results are anticipated, management might issue conservative 2026 guidance to reset market expectations, which could impact short-term stock performance.
- Improving Education Environment: Stephens analyst Charles Nabhan upgraded Flywire from Equal Weight to Overweight and raised the price target from $17 to $19, driven by an improving higher education environment, indicating the company's potential to outperform expectations in the future.
- Growth Levers and Valuation: Analysts highlighted Flywire's various growth levers, deeply discounted valuation, and a strong track record of beat-and-raise earnings quarters as primary reasons for the upgrade, suggesting robust growth momentum in the competitive FinTech sector.
See More
